Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
申请人:Hoffmann-La Roche Inc.
公开号:US06310208B1
公开(公告)日:2001-10-30
Since the compounds in accordance with the invention can bind to serotonin receptors (5HT2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioral disorders, addiction, obesity, bulimia etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases etc.; cardiovascular disorders such as hypertension, thrombosis, stroke etc.; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
由于本发明中的化合物可以结合到5-羟色胺受体(5HT2),因此特别适用于治疗或预防中枢神经系统疾病,如抑郁症、双相情感障碍、焦虑状态、睡眠和性功能障碍、精神病、精神分裂症、偏头痛以及与头痛或其他类型疼痛相关的其他疾病,如人格障碍或强迫症、社交恐惧症或恐慌发作、儿童期的精神障碍、攻击性、与年龄相关的记忆障碍和行为障碍、成瘾、肥胖、暴食症等,以及由创伤、中风、神经退行性疾病等引起的神经系统损伤;心血管疾病,如高血压、血栓形成、中风等;以及胃肠道疾病,如胃肠道运动功能障碍。